Amneal Pharmaceuticals, Inc. (AMRX, Financial) experienced a significant stock price increase of 5.02%, trading at $8.69 per share with a volume of 1.26784 million shares. The turnover rate was 0.41%, and the stock's amplitude reached 5.80%.
Recent financial reports show AMRX achieved revenue of $702 million, with a net loss of $156,000 and earnings per share of $0.00. The company reported a gross profit of $270 million and a negative price-to-earnings ratio of -10.09.
In terms of institutional ratings, 75% of the four participating institutions recommended buying the stock, while 25% suggested holding. No institutions advised selling.
The pharmaceutical sector, where AMRX operates, saw an overall increase of 0.46%. Notable performers included Gelteq Limited, Bomei Group, and Citius Oncology, Inc., while stocks like Painreform Ltd. and Sunshine Biopharma Inc. were highly active.
